ABLI.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:29):

Stats
今日成交量	662 886
平均成交量	1.49M
市值	174.08M
EPS	SEK0 ( 2024-02-22 )
下一个收益日期	( SEK0 ) 2024-05-23
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.830
ATR14	SEK0.00100 (0.61%)

音量相关性

長: -0.11 (neutral)

短: -0.59 (weak negative)

Signal:(55.527) Neutral

Abliva AB (publ) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Abliva AB (publ) 相关性 - 货币/商品

0.00
( neutral )

0.04
( neutral )

0.00
( neutral )

-0.03
( neutral )

Abliva AB (publ) 财务报表

Annual	2023
营收:	SEK137 000
毛利润:	SEK-35.66M (-26 031.39 %)
EPS:	SEK-0.0904

FY	2023
营收:	SEK137 000
毛利润:	SEK-35.66M (-26 031.39 %)
EPS:	SEK-0.0904

FY	2023
营收:	SEK0
毛利润:	SEK0 (0.00 %)
EPS:	SEK0

FY	2022
营收:	SEK31 000.00
毛利润:	SEK-84.91M (-273 887.10 %)
EPS:	SEK-0.110

Financial Reports:

No articles found.

Abliva AB (publ)

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.